Aminoguanidine Prevents the Depletion of Neurons Containing Nitric Oxide Synthase in the Streptozotocin Diabetic Rat

Summary Recently, we demonstrated that nitric oxide synthase immunoreactive (NOS-IR) neurons are closely associated with the retinal vasculature and have proposed that these neurons are the mechanism by which retinal blood flow and metabolism are linked. This study examined the effect of diabetes on the population of NADPH diaphorase (NADPHd)-positive (equivalent to NOS-IR) neurons in the retina. Aminoguanidine (AG), an inhibitor of advanced glycation, has been shown to attenuate AGE accumulation as well as the progression of retinal disease in experimental diabetes. It is known that aminoguanidine also inhibits NOS in vitro. This study investigated the effect of diabetes and aminoguanidine (an inhibitor of advanced glycation) or NG-monomethyl-L-arginine (L-NAME) (an inhibitor of NOS), treatment on the population of NAPDHd-positive amacrine cells in the rat retina. Diabetic and control rats were randomized and received no treatment, aminoguanidine or L-NAME for 32 weeks. Diabetic rats had increased serum glucose levels and blood pressure, but lower body weight compared with controls. The number of NADPHd-positive neurons per retina was significantly reduced (−26%) in diabetic rats compared with control rats. Aminoguanidine treatment of diabetic rats restored the number of NADPHd-positive neurons to normal levels at 32 weeks. L-NAME treatment of diabetic animals had no effect on the number of NADPHd-positive neurons. Since the retinoprotective effect of aminoguanidine cannot be reproduced by L-NAME, it is likely to be mediated by a decrease in advanced glycation rather than by inhibition of NOS.

[1]  M. Cotter,et al.  Contraction and relaxation of aortas from diabetic rats: effects of chronic anti-oxidant and aminoguanidine treatments , 1996, Naunyn-Schmiedeberg's Archives of Pharmacology.

[2]  H. Hammes,et al.  Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model , 1995, Diabetologia.

[3]  M. Cotter,et al.  Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats , 1992, Diabetologia.

[4]  J. Nyengaard,et al.  Discordant Effects of Guanidines on Renal Structure and Function and on Regional Vascular Dysfunction and Collagen Changes in Diabetic Rats , 1997, Diabetes.

[5]  M. Cotter,et al.  Rapid reversal by aminoguanidine of the neurovascular effects of diabetes in rats: modulation by nitric oxide synthase inhibition. , 1996, Metabolism: clinical and experimental.

[6]  A. Karihaloo,et al.  Modulation of basal nitric oxide-dependent cyclic-GMP production by ambient glucose, myo-inositol, and protein kinase C in SH-SY5Y human neuroblastoma cells. , 1996, The Journal of clinical investigation.

[7]  M. Mcdaniel,et al.  Selective inhibition of inducible nitric oxide synthase by aminoguanidine. , 1993, Methods in enzymology.

[8]  S. Rees,et al.  Nitric oxide synthase immunoreactivity and NADPH diaphorase staining are co-localised in neurons closely associated with the vasculature in rat and human retina , 1995, Brain Research.

[9]  M. Cotter,et al.  The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications. , 1994, Diabetes/metabolism reviews.

[10]  E. Feldman,et al.  The linked roles of nitric oxide, aldose reductase and, (Na+,K+)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. , 1994, The Journal of clinical investigation.

[11]  E. Kohner,et al.  The Effect of Aminoguanidine and Tolrestat on Glucose Toxicity in Bovine Retinal Capillary Pericytes , 1994, Diabetes.

[12]  M. Mcdaniel,et al.  Prevention of Diabetic Vascular Dysfunction by Guanidines: Inhibition of Nitric Oxide Synthase Versus Advanced Glycation End-Product Formation , 1993, Diabetes.

[13]  M. Mcdaniel,et al.  Aminoguanidine, a Novel Inhibitor of Nitric Oxide Formation, Prevents Diabetic Vascular Dysfunction , 1992, Diabetes.

[14]  S. Yagihashi,et al.  Effect of Aminoguanidine on Functional and Structural Abnormalities in Peripheral Nerve of STZ-Induced Diabetic Rats , 1992, Diabetes.

[15]  G. Jerums,et al.  Retardation by Aminoguanidine of Development of Albuminuria, Mesangial Expansion, and Tissue Fluorescence in Streptozocin-Induced Diabetic Rat , 1991, Diabetes.

[16]  S. Snyder,et al.  Nitric oxide synthase and neuronal NADPH diaphorase are identical in brain and peripheral tissues. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[17]  P. Low,et al.  Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[18]  K. Tracey,et al.  Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. , 1991, The Journal of clinical investigation.

[19]  H. Chase,et al.  Glucose control and the renal and retinal complications of insulin-dependent diabetes. , 1989, JAMA.

[20]  D L DeMets,et al.  The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. , 1989, Archives of ophthalmology.